Global Oncology Radiopharmaceuticals Market Overview:
Global Oncology Radiopharmaceuticals Market is expected to grow at a significant rate during the forecast period 2026-2035, with 2024 as the base year.
Global Oncology Radiopharmaceuticals Market Report 2026 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2026-2035, with base year as 2025. This research study of Oncology Radiopharmaceuticals involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Oncology Radiopharmaceuticals Market:
The Oncology Radiopharmaceuticals Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Oncology Radiopharmaceuticals Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Oncology Radiopharmaceuticals Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Oncology Radiopharmaceuticals market has been segmented into:
Radium-223 dichloride
Sodium iodide I-131
Lobenguane iodine-131
Lutetium-177
Yttrium-90
Fludeoxyglucose F 18
Gallium Citrate Ga 67
Technetium-99m
and Others
By Application, Oncology Radiopharmaceuticals market has been segmented into:
Oral and Intravenous
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Oncology Radiopharmaceuticals market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Oncology Radiopharmaceuticals market.
Top Key Players Covered in Oncology Radiopharmaceuticals market are:
Siemens Healthcare GmbH
Novartis AG
Curium
GE Healthcare
Lantheus Medical Imaging
Inc.
International Isotopes
Inc.
Nordion
Eckert & Zieger
Acrotech Biopharma
Blue Earth Diagnostics
Zionexa
Bayer AG
Jubilant Pharma Limited
Cardinal Health
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Oncology Radiopharmaceuticals Market by Type
4.1 Oncology Radiopharmaceuticals Market Snapshot and Growth Engine
4.2 Oncology Radiopharmaceuticals Market Overview
4.3 Radium-223 dichloride
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Radium-223 dichloride: Geographic Segmentation Analysis
4.4 Sodium iodide I-131
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Sodium iodide I-131: Geographic Segmentation Analysis
4.5 Lobenguane iodine-131
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Lobenguane iodine-131: Geographic Segmentation Analysis
4.6 Lutetium-177
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 Lutetium-177: Geographic Segmentation Analysis
4.7 Yttrium-90
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.7.3 Key Market Trends, Growth Factors and Opportunities
4.7.4 Yttrium-90: Geographic Segmentation Analysis
4.8 Fludeoxyglucose F 18
4.8.1 Introduction and Market Overview
4.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.8.3 Key Market Trends, Growth Factors and Opportunities
4.8.4 Fludeoxyglucose F 18: Geographic Segmentation Analysis
4.9 Gallium Citrate Ga 67
4.9.1 Introduction and Market Overview
4.9.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.9.3 Key Market Trends, Growth Factors and Opportunities
4.9.4 Gallium Citrate Ga 67: Geographic Segmentation Analysis
4.10 Technetium-99m
4.10.1 Introduction and Market Overview
4.10.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.10.3 Key Market Trends, Growth Factors and Opportunities
4.10.4 Technetium-99m: Geographic Segmentation Analysis
4.11 and Others
4.11.1 Introduction and Market Overview
4.11.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.11.3 Key Market Trends, Growth Factors and Opportunities
4.11.4 and Others: Geographic Segmentation Analysis
Chapter 5: Oncology Radiopharmaceuticals Market by Application
5.1 Oncology Radiopharmaceuticals Market Snapshot and Growth Engine
5.2 Oncology Radiopharmaceuticals Market Overview
5.3 Oral and Intravenous
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Oral and Intravenous: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Oncology Radiopharmaceuticals Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 SIEMENS HEALTHCARE GMBH
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 NOVARTIS AG
6.4 CURIUM
6.5 GE HEALTHCARE
6.6 LANTHEUS MEDICAL IMAGING
6.7 INC.
6.8 INTERNATIONAL ISOTOPES
6.9 INC.
6.10 NORDION
6.11 ECKERT & ZIEGER
6.12 ACROTECH BIOPHARMA
6.13 BLUE EARTH DIAGNOSTICS
6.14 ZIONEXA
6.15 BAYER AG
6.16 JUBILANT PHARMA LIMITED
6.17 AND CARDINAL HEALTH
Chapter 7: Global Oncology Radiopharmaceuticals Market By Region
7.1 Overview
7.2. North America Oncology Radiopharmaceuticals Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Type
7.2.4.1 Radium-223 dichloride
7.2.4.2 Sodium iodide I-131
7.2.4.3 Lobenguane iodine-131
7.2.4.4 Lutetium-177
7.2.4.5 Yttrium-90
7.2.4.6 Fludeoxyglucose F 18
7.2.4.7 Gallium Citrate Ga 67
7.2.4.8 Technetium-99m
7.2.4.9 and Others
7.2.5 Historic and Forecasted Market Size By Application
7.2.5.1 Oral and Intravenous
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe Oncology Radiopharmaceuticals Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Type
7.3.4.1 Radium-223 dichloride
7.3.4.2 Sodium iodide I-131
7.3.4.3 Lobenguane iodine-131
7.3.4.4 Lutetium-177
7.3.4.5 Yttrium-90
7.3.4.6 Fludeoxyglucose F 18
7.3.4.7 Gallium Citrate Ga 67
7.3.4.8 Technetium-99m
7.3.4.9 and Others
7.3.5 Historic and Forecasted Market Size By Application
7.3.5.1 Oral and Intravenous
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Bulgaria
7.3.6.2 The Czech Republic
7.3.6.3 Hungary
7.3.6.4 Poland
7.3.6.5 Romania
7.3.6.6 Rest of Eastern Europe
7.4. Western Europe Oncology Radiopharmaceuticals Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Type
7.4.4.1 Radium-223 dichloride
7.4.4.2 Sodium iodide I-131
7.4.4.3 Lobenguane iodine-131
7.4.4.4 Lutetium-177
7.4.4.5 Yttrium-90
7.4.4.6 Fludeoxyglucose F 18
7.4.4.7 Gallium Citrate Ga 67
7.4.4.8 Technetium-99m
7.4.4.9 and Others
7.4.5 Historic and Forecasted Market Size By Application
7.4.5.1 Oral and Intravenous
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 Netherlands
7.4.6.5 Italy
7.4.6.6 Russia
7.4.6.7 Spain
7.4.6.8 Rest of Western Europe
7.5. Asia Pacific Oncology Radiopharmaceuticals Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Type
7.5.4.1 Radium-223 dichloride
7.5.4.2 Sodium iodide I-131
7.5.4.3 Lobenguane iodine-131
7.5.4.4 Lutetium-177
7.5.4.5 Yttrium-90
7.5.4.6 Fludeoxyglucose F 18
7.5.4.7 Gallium Citrate Ga 67
7.5.4.8 Technetium-99m
7.5.4.9 and Others
7.5.5 Historic and Forecasted Market Size By Application
7.5.5.1 Oral and Intravenous
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa Oncology Radiopharmaceuticals Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Type
7.6.4.1 Radium-223 dichloride
7.6.4.2 Sodium iodide I-131
7.6.4.3 Lobenguane iodine-131
7.6.4.4 Lutetium-177
7.6.4.5 Yttrium-90
7.6.4.6 Fludeoxyglucose F 18
7.6.4.7 Gallium Citrate Ga 67
7.6.4.8 Technetium-99m
7.6.4.9 and Others
7.6.5 Historic and Forecasted Market Size By Application
7.6.5.1 Oral and Intravenous
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkey
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America Oncology Radiopharmaceuticals Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Type
7.7.4.1 Radium-223 dichloride
7.7.4.2 Sodium iodide I-131
7.7.4.3 Lobenguane iodine-131
7.7.4.4 Lutetium-177
7.7.4.5 Yttrium-90
7.7.4.6 Fludeoxyglucose F 18
7.7.4.7 Gallium Citrate Ga 67
7.7.4.8 Technetium-99m
7.7.4.9 and Others
7.7.5 Historic and Forecasted Market Size By Application
7.7.5.1 Oral and Intravenous
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Oncology Radiopharmaceuticals Scope:
|
Report Data
|
Oncology Radiopharmaceuticals Market
|
|
Oncology Radiopharmaceuticals Market Size in 2025
|
USD XX million
|
|
Oncology Radiopharmaceuticals CAGR 2025 - 2032
|
XX%
|
|
Oncology Radiopharmaceuticals Base Year
|
2024
|
|
Oncology Radiopharmaceuticals Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Siemens Healthcare GmbH, Novartis AG, Curium, GE Healthcare, Lantheus Medical Imaging, Inc., International Isotopes, Inc., Nordion, Eckert & Zieger, Acrotech Biopharma, Blue Earth Diagnostics, Zionexa, Bayer AG, Jubilant Pharma Limited, and Cardinal Health.
|
|
Key Segments
|
By Type
Radium-223 dichloride
Sodium iodide I-131
Lobenguane iodine-131
Lutetium-177
Yttrium-90
Fludeoxyglucose F 18
Gallium Citrate Ga 67
Technetium-99m
and Others
By Applications
Oral and Intravenous
|
